Armstrong, A. W.; Papp, K. A.; Zhuo, J.; Becker, B.; Zhong, Y.; Beaumont, J. L.; DeRosa, M.; Kisa, R. M.; Banerjee, S.; Strober, B. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Correlations Between Patient-Reported Outcomes and Clinical Responses in the Phase 3 Clinical Trials POETYK PSO-1 and POETYK PSO-2. J of Skin 2022, 6, s63.